Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced positive topline full study results from the Phase 3 VISIONARY trial. VOYXACT ® ...
A new approach for identifying signs of hidden awareness in people who cannot speak or move after severe brain injury has ...
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today provides shareholders a ...
The wAIHA market landscape is undergoing a significant evolution after years of dependence on broad immunosuppressive ...
Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with ...
Aerospace and Mechanical Insider on MSN
Stimuli-responsive functional molecular liquids explained
Advances in soft materials are reshaping the design of next-generation devices, particularly where flexibility, adaptability, ...
1d
Cohere Technologies Wins $28 Million U.S. Government Contract to Develop Multi-Waveform RAN for ISAC
Multi-Waveform Wireless Prototype Will Deliver Operational Aerial Surveillance and Response ISAC is a mission-first ...
A deep reinforcement learning framework optimizes silicon-based photonic crystal fiber modulators, achieving ultra-low ...
The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...
Durable ZUMA-2 follow-up converted brexu-cel to traditional approval in r/r MCL, while sonrotoclax gained accelerated approval post-BTK inhibitor based on 52% ORR. Breast-cancer decisions expanded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results